Selective estrogen receptor modulators

Current Opinion in Rheumatology

Volumn 11, Issue 4, 1999, Pages 301-306

  Weryha, Georges ^a   Pascal Vigneron, Véronique ^a   Klein, Marc ^a   Leclère, Jacques ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE;

ARTICLE; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; ENDOMETRIUM HYPERPLASIA; HYPOTHESIS; LIPID METABOLISM; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VERTEBRA FRACTURE;

BONE AND BONES; BONE DENSITY; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 0032871364     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199907000-00014     Document Type: Article

References (49)

1. 1 de Lignieres B: Hormone replacement therapy: clinical benefits and side-effects. Maturitas 1996, 23(suppl):31-36.
2. 2 Group EBCTC: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988, 319:1681-1692.
3. 3 Love RR, Mazess RB, Baren HS, Epstein S, Newcomb PA, Jordan VC, et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992, 326:852-856.
4. 4 ACOG committee opinion: Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. In J Gynaecol Obstet 1996, 53:197-199.
5. 5 Jordan VC: Tamoxifen and endometrial cancer [letter]. Lancet 1989, 1:733-734.
6. 6 Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758.
7. 7 Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17B-estradiol and raloxifene. Science 1996, 273:1222-1225.
8. 8 Paech K, Webb P, Kuiper GG, Nilsson, S, Gustafsson J, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERB at AP1 sites. Science 1997, 227:1508-1510.
9. 9 Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, Termine JD: Estrogen and raloxifene stimulate transforming growth factor-B3 gene expression in rate bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 1996, 137:2075-2084.
10. 10 Farhat MY, Lavigne MC, Ramwell PW: The vascular protective effects of estrogen. FASEB J 1996, 10:615-624.
11. 11 Fisher B, Costantine JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388. This NSABP study is the most important database on benefits and side effects of tamoxifen use. NSABP P1 studies the preventive use of tamoxifen.
12. 12 Fradishar WJ, Jordan VC: Clinical potential of new antiestrogens. J Clin Oncol 1997, 15:840-852.
13. 13 Buzdar AU, Hortobagyi GN: Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 1998, 16:348-353.
14. 14 Haarstad H, Lonning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S: Influence of droloxifine on metastatic breast cancer as first-line endocrine treatment. Acta Oncol 1998, 37:365-368.
15. 15 Pace P, Jarmen M, Phillips D, Hewer A, Bliss J, Coombes RC: Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer 1997, 76:700-704.
16. 16 Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin GR, et al.: Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res 1988, 48:6764-6768.
17. 17 Anazano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al.: Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1 996, 88:123-125.
18. 18 Wakeling AE, Valcaccia B: Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. J Endocrinol 1983, 99:455-464.
19. 19 Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988, 45:344-345.
20. 20 Ensrud K, Black D, Recker R, Harris S, Delmas P, Pols H, Reginster J: The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Bone 1998, 45:344-345. Results of the MORE study published at the 1998 American Society for Bone and Mineral Research meeting. Covers multiple aspects of HRT beyond osteoporosis. Publication should follow soon.
21. 21 Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast cancer Res Treat 1988, 12:297-302.
22. 22 Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB: Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 1996, 39:321 -326.
23. 23 Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, et al.: Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the overiectomized rat model. Bone 1997, 20:31-39.
24. 24 Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, et al.: Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in overiectomized rats and decreases uterine weight in intact rats. Endocrinology 1998, 139:5224-5234.
25. 25 Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998, 83:1158-1162.
26. 26 Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, et al.: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in overiectomized rats. J Clin Invest 1994, 93:63-69.
27. 27 Turner CH, Sato M, Bryant HU: Raloxifene preserves bone strength and bone mass in overiectomized rats. Endocrinology 1994, 135:2001-2005.
28. 28 Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997,337:1641-1647.
29. 29 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037.
30. 30 Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, eta l.: The risk of myocardial infarction associated with the combined use of estrogens and progestins in menopausal women. Arch Intern Med 1994, 154:1333-1339.
31. 31 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
32. 32 Bjarnason NH, Haarbo J, Bryjalsen I, Kauffman RF, Christiansen C: Raloxifene inhibits aortic accumulation of cholesterol in overiectomized, cholesterol-fed rabbits. Circulation 1997, 96:1964-1969.
33. 33 Draper MW, Flwers DE, Huster WJ, Neild JA, Harper KD, Arnaud C: A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996, 11:835-842.
34. 34 Grey AB, Stapleton JP, Evans MC, Reid IR: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995, 80:3191-3195.
35. 35 Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445-1451.
36. 36 Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO III: Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1996, 76:1072-1073.
37. 37 Zuckerman SH, Bryan N: inhibition of LDL oxidation and myetoperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 1996, 126:65-75.
38. 38 Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, et al.: Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 1998, 77:2264-2266.
39. 39 Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P: Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998, 70:1085-1089.
40. 40 Ragaz J, Colman A: Survival impact of adjuvant tamoxifen on competing contralateral breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998, 16:2018-2024. This publication attests the reduction of incidence of cardiovascular events in women treated with tamoxifen.
41. 41 Clarkson TB, Anthony MS, Jerome CP: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998, 83:721-726.
42. 42 Gusberg SB: Tamoxifen for breast cancer: associated endometrial cancer. Cancer 1990, 65:1463-1464.
43. 43 Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985, 69:237-238.
44. 44 Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E: Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Reprod Biol 1990, 35:235-238.
45. 45 Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995, 59:261-266.
46. 46 Cummings S, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, et al.: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial [abstract 3]. In Proceedings of the ASCO Meeting, 1998. This oral communication showed the reduction of breast and endometrial cancers among women enrolled in the MORE study.
47. 47 Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996, 14:2731-2737.
48. 48 Veronesi U, Maisonneuvre P, Costa A, Sacchini V, Maaltoni C, Robertson C, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998, 352:93-97.
49. 49 Goldstein SR: Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol 1998, 179:1479-1484.